Chengyi Bio and AstraZeneca Advance Oral Small Molecule GLP-1 Agonist AZD5004 into Two Phase 2b Trials for Obesity and Type 2 Diabetes

▎Armstrong

On August 30, 2024, AstraZeneca registered two Phase 2b clinical trials for the small molecule GLP-1 receptor agonist AZD5004 on the Clinicaltrials.gov website, for the treatment of type 2 diabetes and obesity, respectively.

The Phase 2b clinical trial for obesity plans to enroll 285 patients and is expected to be completed by the end of 2025. The Phase 2b clinical trial for type 2 diabetes plans to enroll 384 patients and is also expected to be completed by the end of 2025.

Eccogene R&D Pipeline Report: Small Molecule GLP-1 Receptor Agonist, THR-β Agonist, SSAO Inhibitor, and the First Three ProductsAverageEntering the clinical stage.

In November 2023, Eccogene licensed the overseas rights of its GLP-1 project to AstraZeneca. AstraZeneca paid $185 million as an upfront payment, $1.825 billion in milestone payments, and a specific percentage of sales royalties.

Summary

In May 2024, according to Endpoints News, Eccogene plans to go public on Nasdaq in early 2025, and may conduct a crossover round of financing before that.